Literature DB >> 11150276

Living related conjunctival limbal allograft for the treatment of stem cell deficiency.

S M Daya1, F A Ilari.   

Abstract

PURPOSE: To evaluate the outcomes of living related conjunctival limbal allograft transplantation for the treatment of stem cell deficiency.
DESIGN: Retrospective, noncomparative case series. PARTICIPANTS: Nine living related donors, eight recipients (10 eyes) with Stevens-Johnson syndrome (3 eyes), ectodermal dysplasia (3 eyes), chemical injury (2 eyes), ocular cicatricial pemphigoid (1 eye), and atopic keratoconjunctivitis (n = 1). INTERVENTION: Four clock hours of limbal conjunctival tissue from the best matched human leukocyte antigen (HLA) relative donor were transplanted to the recipient eye superiorly and inferiorly after conjunctival peritomy and removal of conjunctival pannus. Systemic cyclosporine was administered to all recipients. MAIN OUTCOME MEASURES: Restoration of corneal epithelium, reduction of vascularity and conjunctivalization, improved comfort, improved corneal clarity, and visual improvement.
RESULTS: Mean follow-up period was 26.2 months. Two highly inflamed eyes failed to initially epithelialize. The remainder all survived with restoration of corneal epithelium and reduction of vascularization. Corneal opacification was reduced (four of eight eyes) and visual improvement was achieved in seven eyes. All five eyes with pain had an improvement in symptoms. Allograft rejection occurred in two eyes (25%), and both were treated successfully. Both eyes had two class I HLA mismatches, and both had an underlying diagnosis of Stevens-Johnson syndrome. One eye developed a recurrent epithelial defect and perforated, requiring a penetrating keratoplasty that remained clear with an intact epithelial surface. The two initial failures also perforated and required penetrating keratoplasties that failed. None of the donor eyes had any complications.
CONCLUSIONS: Restoration of the ocular surface by HLA-matched conjunctival limbal allograft transplantation can be accomplished in selected recipients. Systemic cyclosporine, even at low doses, is useful in ensuring long-term survival.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11150276     DOI: 10.1016/s0161-6420(00)00475-9

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  21 in total

1.  Limbal stem cell disease: Treatment and advances in technology.

Authors:  Hall F Chew
Journal:  Saudi J Ophthalmol       Date:  2011-05-24

Review 2.  Graft failure: II. Ocular surface complications.

Authors:  Samar A Al-Swailem
Journal:  Int Ophthalmol       Date:  2008-06       Impact factor: 2.031

3.  Personalized Stem Cell Therapy to Correct Corneal Defects Due to a Unique Homozygous-Heterozygous Mosaicism of Ectrodactyly-Ectodermal Dysplasia-Clefting Syndrome.

Authors:  Vanessa Barbaro; Annamaria Assunta Nasti; Paolo Raffa; Angelo Migliorati; Patrizia Nespeca; Stefano Ferrari; Elisa Palumbo; Marina Bertolin; Claudia Breda; Francesco Miceli; Antonella Russo; Luciana Caenazzo; Diego Ponzin; Giorgio Palù; Cristina Parolin; Enzo Di Iorio
Journal:  Stem Cells Transl Med       Date:  2016-05-05       Impact factor: 6.940

4.  Global Consensus on Definition, Classification, Diagnosis, and Staging of Limbal Stem Cell Deficiency.

Authors:  Sophie X Deng; Vincent Borderie; Clara C Chan; Reza Dana; Francisco C Figueiredo; José A P Gomes; Graziella Pellegrini; Shigeto Shimmura; Friedrich E Kruse
Journal:  Cornea       Date:  2019-03       Impact factor: 2.651

5.  Diagnostic criteria for limbal stem cell deficiency before surgical intervention-A systematic literature review and analysis.

Authors:  Qihua Le; Tulika Chauhan; Sophie X Deng
Journal:  Surv Ophthalmol       Date:  2019-07-02       Impact factor: 6.048

6.  Allogenic cultivated limbal stem cell transplantation versus cadaveric keratolimbal allograft in ocular surface disorder: 1-year outcome.

Authors:  Jitendra Kumar Singh Parihar; Avinash Singh Parihar; Vaibhav Kumar Jain; Jaya Kaushik; Pramod Nath
Journal:  Int Ophthalmol       Date:  2016-12-26       Impact factor: 2.031

Review 7.  Current and emerging therapies for corneal neovascularization.

Authors:  Danial Roshandel; Medi Eslani; Alireza Baradaran-Rafii; Albert Y Cheung; Khaliq Kurji; Sayena Jabbehdari; Alejandra Maiz; Setareh Jalali; Ali R Djalilian; Edward J Holland
Journal:  Ocul Surf       Date:  2018-06-20       Impact factor: 5.033

8.  Limbal stem cell transplantation: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2008-10-01

Review 9.  Limbal stem cell transplantation: new progresses and challenges.

Authors:  L Liang; H Sheha; J Li; S C G Tseng
Journal:  Eye (Lond)       Date:  2008-12-19       Impact factor: 3.775

Review 10.  Current and Upcoming Therapies for Ocular Surface Chemical Injuries.

Authors:  Alireza Baradaran-Rafii; Medi Eslani; Zeeshan Haq; Ebrahim Shirzadeh; Michael J Huvard; Ali R Djalilian
Journal:  Ocul Surf       Date:  2016-09-17       Impact factor: 5.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.